PCVX
Live chart
What they do
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
For information only · Important disclosures
Grades vs sector
No sector grades for PCVX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | -2.10 | -1.97 | +6.1% |
| 2026-05-06 | -1.77 | -2.30 | -29.6% |
| 2026-02-24 | -1.50 | -1.80 | -19.7% |
| 2025-11-04 | -1.24 | -1.56 | -26.3% |
| 2025-08-06 | -1.16 | -1.22 | -5.0% |
| 2025-05-07 | -0.97 | -1.04 | -6.7% |
| 2025-02-25 | -0.99 | -1.02 | -2.6% |
| 2024-11-05 | -0.99 | -0.83 | +16.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Analyst actions
PT $120
PT $89
PT $122
PT $125
PT $130
PT $110
Stats refreshed 2026-10-21 13:45:30 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026